Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00689884 · ClinicalTrials.gov registry record · NA
Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00689884 is a NA study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT00689884, a NA study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells (PBSCs), defined as cell yield ≥ 3 x 10e6 CD34+/kg and to assess the costs related to Pegfilgrastim use in the mobilization of autologous PBSCs. Also to determine the side effects of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells.
Interventions
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00689884
The ClinicalTrials.gov registry entry for NCT00689884 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegfilgrastim is the first listed.
NCT00689884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00689884 about?
NCT00689884 is a clinical study titled "Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies". The purpose of this study is to determine the efficacy of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells (PBSCs), defined as cell yield ≥ 3 x 10e6 CD34+/kg and to assess the costs related to Pegfilgrastim use in the mobilization of autologous PBSCs. Also to determine the...
What is the current status of trial NCT00689884?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2007-01. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00689884?
The interventions under investigation include: Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT00689884?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.